TWD 70.8
(0.28%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 68.23 Million TWD | 12.49% |
2022 | 60.65 Million TWD | 380.39% |
2021 | 12.62 Million TWD | -47.12% |
2020 | 23.88 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 65.14 Million TWD | 0.0% |
2024 Q1 | 66.69 Million TWD | 0.0% |
2023 Q2 | 71.29 Million TWD | 0.0% |
2023 FY | 68.23 Million TWD | 12.49% |
2023 Q4 | 68.23 Million TWD | 0.0% |
2023 Q3 | - TWD | -100.0% |
2023 Q1 | - TWD | -100.0% |
2022 FY | 60.65 Million TWD | 380.39% |
2022 Q4 | 60.65 Million TWD | 0.0% |
2021 FY | 12.62 Million TWD | -47.12% |
2020 FY | 23.88 Million TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Apex Biotechnology Corp. | 116.19 Million TWD | 41.275% |
Sinphar Pharmaceutical Co.,Ltd. | 1.49 Billion TWD | 95.433% |
Panion & Bf Biotech Inc. | 125.41 Million TWD | 45.593% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 700 Million TWD | 90.252% |
GenMont Biotech Incorporation | 20.11 Million TWD | -239.28% |
Abnova (Taiwan) Corporation | 2.6 Million TWD | -2523.453% |
Adimmune Corporation | 1.91 Billion TWD | 96.442% |
Tanvex BioPharma, Inc. | 1.56 Billion TWD | 95.649% |
Polaris Group | 352.96 Million TWD | 80.668% |
Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
PELL Bio-Med Technology Co. Ltd. | 147.46 Million TWD | 53.728% |